2023 World Conference on Lung Cancer (Posters)-EP12.01. Successful Aumolertinib Treatment of Activated EGFR Mutation NSCLC Patients with Interstitial Pneumonia Induced by Osimertinib

EP12.01. Successful Aumolertinib Treatment of Activated EGFR Mutation NSCLC Patients with Interstitial Pneumonia Induced by Osimertinib - PDF(Slides)

Back to course

Pdf Summary

A recent study evaluated the safety and efficacy of aumolertinib in lung cancer patients with interstitial lung disease (ILD) induced by osimertinib. Osimertinib is a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) commonly used to treat EGFR-sensitive and resistant non-small cell lung cancer (NSCLC). However, ILD is a potentially fatal side effect of osimertinib treatment. <br /><br />The study included 16 NSCLC patients who developed ILD after receiving osimertinib treatment for a period of 13 days to 8 months. After discontinuing osimertinib and receiving symptomatic treatments, the patients' ILD symptoms improved. They were then rechallenged with aumolertinib, another EGFR-TKI, and received this treatment for a range of 4 to 33 months without ILD recurrence. <br /><br />The primary endpoint of the study was the 3-month conversion success rate, defined as the proportion of patients who did not experience grade 3 or above adverse events within 3 months of switching to aumolertinib treatment. The study found that the 3-month conversion success rate was 100%, indicating that aumolertinib was effective in preventing ILD recurrence in these patients. The disease control rate (DCR) was also 100%, with 4 patients achieving partial response and 8 patients still receiving treatment. The median duration of treatment with aumolertinib was 15 months, and no grade 3 or above adverse reactions occurred. <br /><br />Based on these findings, the study concluded that aumolertinib provides a new treatment option for NSCLC patients who develop ILD after osimertinib treatment. Aumolertinib not only resulted in a survival benefit but also did not cause ILD. <br /><br />The study authors expressed their gratitude to the study participants, their families, caregivers, and all staff involved in the trial for their contributions.

Asset Subtitle

Enguo Chen

Meta Tag

Speaker Enguo Chen

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

aumolertinib

lung cancer

interstitial lung disease

osimertinib

epidermal growth factor receptor

tyrosine kinase inhibitor

non-small cell lung cancer

ILD recurrence prevention

3-month conversion success rate

disease control rate